Source:http://linkedlifedata.com/resource/pubmed/id/10335933
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1999-6-24
|
| pubmed:abstractText |
The effects and interaction of endocrine and cytotoxic adjuvant treatment on measures of cellular immunity were assessed in 41 stage I-II breast cancer patients from International Breast Cancer Study Group trials. Counts of lymphocytes and lymphocyte subsets [(T, T4, T8, B, natural killer (NK) and activated T (AT) cells] were assessed by flow cytometry immediately before adjuvant therapy at baseline and on day 1 of the 3rd cycle. Twenty-two patients received cyclophosphamide, methotrexate and 5-fluorouracil (CMF), 7 CMF and tamoxifen (TAM), and 12 TAM alone. On day 1 of the 3rd cycle the counts of total lymphocytes (P = 0.003) and all lymphocyte subsets (P<0.05) except AT cells were significantly lower than baseline in the CMF treatment group. There was no significant change in the CMF+TAM or in the TAM treatment group. The combination of CMF and TAM resulted in less pronounced decrease in lymphocyte and subset counts from baseline to day 1 of the 3rd cycle. It seems possible that there is an interaction between TAM with CMF that affects lymphocyte and lymphocyte subset counts during cytotoxic treatment.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0941-4355
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
7
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
149-53
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10335933-Adult,
pubmed-meshheading:10335933-Aged,
pubmed-meshheading:10335933-Antineoplastic Agents, Hormonal,
pubmed-meshheading:10335933-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10335933-B-Lymphocyte Subsets,
pubmed-meshheading:10335933-Breast Neoplasms,
pubmed-meshheading:10335933-Chemotherapy, Adjuvant,
pubmed-meshheading:10335933-Cisplatin,
pubmed-meshheading:10335933-Combined Modality Therapy,
pubmed-meshheading:10335933-Drug Interactions,
pubmed-meshheading:10335933-Female,
pubmed-meshheading:10335933-Flow Cytometry,
pubmed-meshheading:10335933-Fluorouracil,
pubmed-meshheading:10335933-Humans,
pubmed-meshheading:10335933-Methotrexate,
pubmed-meshheading:10335933-Middle Aged,
pubmed-meshheading:10335933-T-Lymphocyte Subsets,
pubmed-meshheading:10335933-Tamoxifen
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients.
|
| pubmed:affiliation |
Medical Division Lory-Haus, University Hospital Insel, Berne, Switzerland. marzio.sabbioni@insel.ch
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|